Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial.

Arnauld C VerschuurViera BajčiováLeo MascarenhasReza KhosravanXun LinAntonella IngrossoKatherine A Janeway

Published in: Cancer chemotherapy and pharmacology (2019)

The tolerable dose of sunitinib in chemotherapy-naïve pediatric patients is at least 20 mg/m2 on schedule 4/2. The safety profile and PK of sunitinib in pediatric patients with GIST are comparable to those in adults.

Keyphrases

metastatic renal cell carcinoma
renal cell carcinoma
clinical trial
study protocol
phase iii
randomized controlled trial
phase ii
squamous cell carcinoma
radiation therapy
young adults